GeoVax Labs, Inc.
As of Oct 22, 2026, GeoVax Labs is in Stage 4, the downtrend phase, now in week 14 (since Jul 20, 2026). It closed at $0.21, 98.6% below its 52-week high and below its 200-day average, which is falling.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is GOVX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
GOVX among Biotechnology541st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …541 | GOVX | Stage 4 · wk 14 | 3 | −43.7% |
GeoVax Labs: quick answers
What stage is GeoVax Labs in?
As of Oct 22, 2026, GeoVax Labs (GOVX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 20, 2026 and is in week 14. What the four stages mean
Is GeoVax Labs in an uptrend?
No. GeoVax Labs is in a Stage 4 downtrend. It trades 84.5% below its 200-day average, which is falling.
How far is GeoVax Labs from its 52-week high?
GeoVax Labs closed at $0.21 on Oct 22, 2026, 98.6% below its 52-week high of $14.98. Its 52-week low is $0.21.
How has GeoVax Labs performed over the past year?
As of Oct 22, 2026, GeoVax Labs is down 98.5% over the past year and down 95.9% so far in 2026.
Which sector and industry is GeoVax Labs in?
GeoVax Labs is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.